A multicenter retrospective analysis of nivolumab in advanced melanoma during the French Temporary Authorization Use.

S. Monestier,S. Dalle,L. Mortier,C. Dutriaux,S. Dalac-Rat,Nicolas Meyer,Marie Thérèse Leccia,Sandrine Mansard,Jean-Philippe Lacour,P. Saiag,Patrick Combemale,B. Guillot,F. Skowron,Pascal Joly,Nathalie Beneton,Ewa Hainaut,Nabahet Ameur,Emilie Varey,Amir Khammari,B. Dreno

A multicenter retrospective analysis of nivolumab in advanced melanoma during the French Temporary Authorization Use.

2018

e21598Background: Nivolumab was the first anti-PD1 therapy to receive a European marketed authorization for the treatment of advanced (unresectable or metastatic) melanoma. To collect and evaluate ...

Keywords:

Physical therapy
Nivolumab
Melanoma
Authorization
Medicine
Oncology
advanced melanoma
Internal medicine
retrospective analysis

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations